Knights of Columbus Asset Advisors’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.44M Sell
14,071
-5,606
-28% -$1.22M 0.17% 130
2026
Q1
$3.33M Sell
19,677
-129
-0.7% -$22.3K 0.19% 120
2025
Q4
$3.62M Sell
19,806
-620
-3% -$86.6K 0.21% 115
2025
Q3
$2.48M Buy
20,426
+514
+3% +$57.9K 0.14% 161
2025
Q2
$2.08M Buy
19,912
+3,932
+25% +$416K 0.13% 178
2025
Q1
$1.86M Sell
15,980
-4,957
-24% -$565K 0.13% 176
2024
Q4
$1.77M Buy
20,937
+52
+0.2% +$4.78K 0.12% 202
2024
Q3
$1.88M Sell
20,885
-11,625
-36% -$1.01M 0.12% 192
2024
Q2
$2.62M Buy
32,510
+9,957
+44% +$737K 0.17% 183
2024
Q1
$1.8M Buy
+22,553
New +$1.89M 0.13% 207
2021
Q3
Sell
-22,142
Closed -$1.49M 306
2021
Q2
$1.49M Buy
22,142
+4,054
+22% +$243K 0.14% 217
2021
Q1
$1.02M Sell
18,088
-220
-1% -$15.5K 0.1% 242
2020
Q4
$1.49M Buy
18,308
+3,352
+22% +$251K 0.16% 228
2020
Q3
$1.07M Sell
14,956
-2,211
-13% -$172K 0.13% 234
2020
Q2
$1.41M Buy
17,167
+2,023
+13% +$156K 0.17% 188
2020
Q1
$891K Buy
+15,144
New +$1.23M 0.11% 258

Other funds holding AXSM

Knights of Columbus Asset Advisors's AXSM Position: Q2 2026 in Review

Knights of Columbus Asset Advisors reduced its Axsome Therapeutics (AXSM) stake by 28% in Q2 2026, selling an estimated $1.22M and leaving 14,071 shares worth $3.44M. The position accounts for 0.17% of the portfolio, ranked #130.

Knights of Columbus Asset Advisors first reported a position in AXSM in Q1 2020 and has held it in 16 quarters since. The position peaked at $3.62M in Q4 2025. 143 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Knights of Columbus Asset Advisors held 14,071 shares of Axsome Therapeutics worth $3.44M as of Q2 2026.
  • Knights of Columbus Asset Advisors sold 5,606 Axsome Therapeutics shares in Q2 2026, an estimated $1.22M.
  • Axsome Therapeutics made up 0.17% of Knights of Columbus Asset Advisors's portfolio in Q2 2026, its #130 holding.
  • Knights of Columbus Asset Advisors first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 16 quarters since.
  • Knights of Columbus Asset Advisors's Axsome Therapeutics position peaked at $3.62M in Q4 2025.
  • 143 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Knights of Columbus Asset Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.